Cell & Gene Therapy Manufacturing Services Market by Service Type (Analytical & Quality Control Services, Cell Banking Services, Consulting Services), Technology Type (Gene Editing, Vectors), Therapeutic Area, Application, End-User - Global Forecast 2025-
Description
The Cell & Gene Therapy Manufacturing Services Market was valued at USD 19.98 billion in 2024 and is projected to grow to USD 23.06 billion in 2025, with a CAGR of 16.30%, reaching USD 66.92 billion by 2032.
Framing the strategic importance of manufacturing services as the pivotal enabler for translating cell and gene therapies from discovery into reliable clinical and commercial supply
The maturation of cell and gene therapy as a therapeutic modality has shifted manufacturing from a niche technical exercise to a strategic capability that determines clinical translational success and long-term commercial viability. Manufacturing services now sit at the intersection of scientific innovation, regulatory complexity, and supply chain resilience, requiring stakeholders to reassess partnerships, capacity models, and technology choices. This introduction synthesizes the operational, regulatory, and market-facing pressures that define current decision horizons for sponsors, contract manufacturers, and technology developers.
Looking ahead, leaders must integrate cross-functional insights across process development, analytical testing, and vector production to streamline handoffs between discovery and commercial supply. The interplay between advanced gene editing techniques, evolving vector platforms, and specialized GMP manufacturing services creates new orchestration demands that impact program timelines and risk profiles. By framing these dynamics early, organizations can better prioritize investment in capability building, partner selection, and regulatory engagement to reduce time-to-patient and increase the robustness of supply continuity.
How technological advances, regulatory clarifications, and supply continuity pressures are rewriting the rules of cell and gene therapy manufacturing operations and partnerships
The landscape for cell and gene therapy manufacturing is undergoing transformative shifts driven by technological breakthroughs, regulatory evolution, and changing commercial expectations. Advances in gene editing such as CRISPR/Cas9 have accelerated the range of addressable indications, while the concurrent development of diversified viral and non-viral vectors has expanded formulation and delivery options. These scientific advances compel manufacturers and service providers to reconfigure workflows, invest in modular facilities, and adopt platform-based approaches that support multiple therapeutic constructs with minimal redeployment time.
Concurrently, regulatory bodies are clarifying expectations around quality attributes, comparability, and long-term follow up, prompting earlier and more integrated engagement between developers and regulators. This regulatory tightening, combined with heightened scrutiny on supply chain integrity and cold-chain logistics, encourages sponsors to prioritize supply continuity and risk mitigation from early clinical stages. As a result, the ecosystem is shifting toward collaborative, vertically integrated partnerships where contract development and manufacturing organizations, specialty CROs, and technology licensors co-design development plans that optimize scalability, regulatory compliance, and cost efficiency.
Operational and procurement recalibrations driven by tariff changes that are reshaping sourcing, inventory strategies, and domestic supplier qualification for critical manufacturing inputs
The introduction of new tariff measures in the United States for 2025 has reoriented operational planning, sourcing strategies, and cost-avoidance tactics for stakeholders in the cell and gene therapy manufacturing value chain. Organizations are reassessing where critical inputs such as plasmid DNA, single-use assemblies, and specialized reagents are procured, as tariffs alter the relative economics of importing versus localizing critical manufacturing supplies. This rebalancing influences decisions on inventory strategy, supplier redundancy, and nearshoring of manufacturing steps to minimize exposure to added duties.
In response, many companies are accelerating qualification of domestic suppliers and exploring multi-sourcing arrangements that reduce single-point dependencies. Plant layout and procurement strategies are being revisited to accommodate more localized supply flows, with some stakeholders expanding domestic fill-and-finish or analytical testing capabilities as a hedge against tariff-driven cost variability. Simultaneously, increased tariff pressure has stimulated creative contractual protections, such as price-indexed supplier agreements and pass-through clauses for critical inputs, allowing developers and service providers to share tariff risk while preserving program timelines and product quality.
Integrated segmentation analysis revealing how service offerings, technology selections, therapeutic focus, application stage, and end-user profiles jointly determine manufacturing strategy and partner selection
A nuanced segmentation approach reveals where service demand, technological choice, therapeutic priorities, application stage, and end-user orientation converge to shape program-level decision making. When assessing offerings by service type, manufacturers and sponsors are aligning needs across analytical and quality control services, cell banking services, consulting services, fill and finish services, GMP manufacturing services, process development services, regulatory support services, supply chain and logistics services, technology transfer services, and vector production services in order to assemble end-to-end workflows that reduce clinical risk and accelerate downstream scalability. Regarding technology type, program teams must weigh gene editing modalities such as CRISPR/Cas9, transcription activator-like effector nucleases, and zinc finger nucleases against vector options; within vectors, choices span non-viral approaches like cationic lipids, chitosan-based vectors, dendrimers, inorganic nanoparticles, liposomes, naked DNA/RNA, peptide-based vectors, and polymeric vectors, as well as viral platforms including adeno-associated virus vectors, adenovirus vectors, herpes simplex virus vectors, and retrovirus vectors, each presenting distinct manufacturing, analytics, and regulatory implications.
Therapeutic area segmentation further influences manufacturing strategy because the requirements for cardiovascular diseases, infectious diseases, monogenic disorders, and oncology vary in terms of patient population, dosing paradigms, and safety monitoring; cardiovascular programs focused on coronary artery disease or heart failure will prioritize scalable delivery and safety profiling, while infectious disease programs targeting hepatitis B or HIV emphasize robust vector dilution controls and durability metrics, and monogenic disorder programs for cystic fibrosis, hemophilia, or sickle cell anemia require highly personalized cell banking and cryopreservation logistics. Oncology programs addressing hematological malignancies and solid tumors impose different demands on cell expansion, potency assays, and release criteria. Application segmentation distinguishes clinical manufacturing from commercial manufacturing, and that distinction drives decisions around facility design, quality system maturity, and process robustness. Finally, end-user segmentation identifies the primary buyers and operators-contract research organizations, hospitals and clinics, pharmaceutical and biotech companies, and research institutes and academic institutions-each of which brings unique operational capabilities, procurement behaviors, and expectations for service level, turnaround time, and regulatory partnership.
How regional regulatory diversity, supply chain infrastructure, and clinical ecosystem strength are driving differentiated capacity planning and partnership models across global markets
Regional dynamics materially influence commercial strategy, capacity planning, and regulatory engagement as manufacturers and sponsors expand or consolidate operations. In the Americas, continuity of innovation, established clinical trial networks, and proximity to major commercial payers drive demand for scalable GMP manufacturing and robust analytics, encouraging investments in domestic fill-and-finish and vector production to support rapid clinical progression and commercialization readiness. Meanwhile, Europe, Middle East & Africa presents a heterogeneous regulatory and reimbursement landscape where early regulatory alignment and localized quality expectations necessitate flexible technology transfer approaches and region-specific supply chain adaptations, prompting multiregional qualification activities and tailored regulatory support services. The Asia-Pacific region combines manufacturing scale, cost-competitive supplier ecosystems, and rapidly growing R&D activity, which attracts investments in high-throughput production platforms and strategic partnerships, but stakeholders must contend with variable regulatory timelines and import-export controls that require nuanced logistical planning.
Across these geographies, cross-border collaboration and knowledge transfer remain essential. Decisions around where to site capacity, establish regional quality control laboratories, or partner with local clinical sites require evaluating not only cost and access but also regulatory harmonization, skilled workforce availability, and cold-chain infrastructure. As a result, successful players balance global platform standardization with regional adaptability to ensure compliance, supply resilience, and clinical continuity across heterogeneous markets.
Competitive differentiation in manufacturing services driven by GMP proficiency, integrated platform capabilities, and demonstrated regulatory support across complex program lifecycles
Competitive dynamics among service providers and technology suppliers are reshaping vendor selection criteria and partnership models. Leading companies differentiate through demonstrable GMP experience, validated analytics, scalable vector production capabilities, and robust technology transfer frameworks that reduce time and risk during scale-up. Strategic collaborations between CDMOs, specialty CROs, and platform technology owners create vertically integrated service suites that appeal to sponsors seeking single-source accountability for complex programs. At the same time, niche providers that offer deep expertise in areas such as viral vector manufacturing, advanced analytical testing, or cold-chain logistics capture value by solving specific technical bottlenecks during pivotal clinical phases.
Investor activity and strategic M&A continue to reconfigure the competitive landscape, as larger players seek to broaden service breadth while smaller, agile vendors emphasize speed and technical depth. Customers increasingly evaluate partners not only on cost and capacity but also on proven regulatory submissions, data integrity practices, and the ability to manage long-term stability and comparability. Consequently, the vendor selection process now prioritizes demonstrable end-to-end capabilities, transparent quality systems, and the capacity to co-develop transfer documents and control strategies that align with global regulatory expectations.
Actionable strategic priorities for leaders to enhance resilience, accelerate scale-up, and de-risk commercialization through modular manufacturing, supplier diversification, and proactive regulatory alignment
Industry leaders should prioritize building modular, platform-enabled manufacturing strategies that allow rapid pivoting across product formats while minimizing revalidation time. Investing in interoperable quality systems and standardized technology transfer templates enables smoother handoffs between development and commercial operations, improving timeline predictability. Additionally, cultivating a diversified supplier network and qualifying alternate domestic sources for critical reagents and disposables reduces exposure to tariff-induced and geopolitical supply disruptions, thereby enhancing program resilience.
Leaders should also embed regulatory engagement early and often, using iterative comparability plans and alignment meetings to de-risk late-stage surprises. Where appropriate, pursuing collaborative partnerships with specialized vendors for vector production, advanced analytics, or fill-and-finish services provides access to niche expertise without the capital burden of in-house expansion. Finally, workforce development and cross-training within facilities will be essential to maintain operational flexibility; investing in training programs and knowledge retention systems ensures that process know-how migrates smoothly across sites and partners, preserving quality and accelerating scale-up.
Robust mixed-method research approach combining expert interviews, vendor capability assessments, and documentary analysis to produce decision-oriented operational insights
This research synthesizes primary and secondary evidence, combining expert interviews, vendor capability assessments, and documentary analysis of regulatory guidance and industry practices. Primary inputs include structured interviews with manufacturing leaders, technology licensors, and clinical operations executives to capture real-world constraints and decision criteria. Secondary analysis encompasses public regulatory documents, technical white papers, peer-reviewed literature on gene editing and vector biology, and corporate disclosures that illustrate operational strategies and investment priorities.
Data synthesis follows a qualitative triangulation approach: themes identified in interviews are cross-validated against technical literature and vendor documentation to ensure consistency. Vendor capability matrices and process archetypes were created to compare service models, while case examples illustrate common pitfalls in technology transfer and scale-up. Throughout the methodology, emphasis was placed on preserving confidentiality of interview respondents and ensuring that analytical frameworks reflect current regulatory landscapes and technological realities. This mixed-method approach yields practical, decision-oriented insights without relying on proprietary market-sizing or forecasting models.
Synthesis of strategic imperatives emphasizing modular platforms, integrated regulatory planning, and supply resilience as prerequisites for successful translation of cell and gene therapies
In conclusion, cell and gene therapy manufacturing services now represent a strategic fulcrum that separates high-velocity development programs from those constrained by capacity, regulatory friction, or supply chain fragility. The interplay of advanced gene editing techniques, diversified vector platforms, and heightened regulatory attention demands a recalibration of partnership models, facility design, and supply resilience strategies. Organizations that adopt modular manufacturing platforms, institutionalize rigorous technology transfer practices, and cultivate diversified supplier networks will be better positioned to translate scientific promise into consistent clinical supply and sustainable commercial operations.
Moving forward, leaders should treat manufacturing strategy as an integrated component of therapeutic development rather than a downstream operational concern. By aligning technical choices, regulatory planning, and procurement strategy from early stages, sponsors and service providers can reduce program risk, accelerate patient access, and create enduring competitive advantage. The path to reliable supply is paved by intentional design, collaborative partnerships, and disciplined execution across the entire development continuum.
Note: PDF & Excel + Online Access - 1 Year
Framing the strategic importance of manufacturing services as the pivotal enabler for translating cell and gene therapies from discovery into reliable clinical and commercial supply
The maturation of cell and gene therapy as a therapeutic modality has shifted manufacturing from a niche technical exercise to a strategic capability that determines clinical translational success and long-term commercial viability. Manufacturing services now sit at the intersection of scientific innovation, regulatory complexity, and supply chain resilience, requiring stakeholders to reassess partnerships, capacity models, and technology choices. This introduction synthesizes the operational, regulatory, and market-facing pressures that define current decision horizons for sponsors, contract manufacturers, and technology developers.
Looking ahead, leaders must integrate cross-functional insights across process development, analytical testing, and vector production to streamline handoffs between discovery and commercial supply. The interplay between advanced gene editing techniques, evolving vector platforms, and specialized GMP manufacturing services creates new orchestration demands that impact program timelines and risk profiles. By framing these dynamics early, organizations can better prioritize investment in capability building, partner selection, and regulatory engagement to reduce time-to-patient and increase the robustness of supply continuity.
How technological advances, regulatory clarifications, and supply continuity pressures are rewriting the rules of cell and gene therapy manufacturing operations and partnerships
The landscape for cell and gene therapy manufacturing is undergoing transformative shifts driven by technological breakthroughs, regulatory evolution, and changing commercial expectations. Advances in gene editing such as CRISPR/Cas9 have accelerated the range of addressable indications, while the concurrent development of diversified viral and non-viral vectors has expanded formulation and delivery options. These scientific advances compel manufacturers and service providers to reconfigure workflows, invest in modular facilities, and adopt platform-based approaches that support multiple therapeutic constructs with minimal redeployment time.
Concurrently, regulatory bodies are clarifying expectations around quality attributes, comparability, and long-term follow up, prompting earlier and more integrated engagement between developers and regulators. This regulatory tightening, combined with heightened scrutiny on supply chain integrity and cold-chain logistics, encourages sponsors to prioritize supply continuity and risk mitigation from early clinical stages. As a result, the ecosystem is shifting toward collaborative, vertically integrated partnerships where contract development and manufacturing organizations, specialty CROs, and technology licensors co-design development plans that optimize scalability, regulatory compliance, and cost efficiency.
Operational and procurement recalibrations driven by tariff changes that are reshaping sourcing, inventory strategies, and domestic supplier qualification for critical manufacturing inputs
The introduction of new tariff measures in the United States for 2025 has reoriented operational planning, sourcing strategies, and cost-avoidance tactics for stakeholders in the cell and gene therapy manufacturing value chain. Organizations are reassessing where critical inputs such as plasmid DNA, single-use assemblies, and specialized reagents are procured, as tariffs alter the relative economics of importing versus localizing critical manufacturing supplies. This rebalancing influences decisions on inventory strategy, supplier redundancy, and nearshoring of manufacturing steps to minimize exposure to added duties.
In response, many companies are accelerating qualification of domestic suppliers and exploring multi-sourcing arrangements that reduce single-point dependencies. Plant layout and procurement strategies are being revisited to accommodate more localized supply flows, with some stakeholders expanding domestic fill-and-finish or analytical testing capabilities as a hedge against tariff-driven cost variability. Simultaneously, increased tariff pressure has stimulated creative contractual protections, such as price-indexed supplier agreements and pass-through clauses for critical inputs, allowing developers and service providers to share tariff risk while preserving program timelines and product quality.
Integrated segmentation analysis revealing how service offerings, technology selections, therapeutic focus, application stage, and end-user profiles jointly determine manufacturing strategy and partner selection
A nuanced segmentation approach reveals where service demand, technological choice, therapeutic priorities, application stage, and end-user orientation converge to shape program-level decision making. When assessing offerings by service type, manufacturers and sponsors are aligning needs across analytical and quality control services, cell banking services, consulting services, fill and finish services, GMP manufacturing services, process development services, regulatory support services, supply chain and logistics services, technology transfer services, and vector production services in order to assemble end-to-end workflows that reduce clinical risk and accelerate downstream scalability. Regarding technology type, program teams must weigh gene editing modalities such as CRISPR/Cas9, transcription activator-like effector nucleases, and zinc finger nucleases against vector options; within vectors, choices span non-viral approaches like cationic lipids, chitosan-based vectors, dendrimers, inorganic nanoparticles, liposomes, naked DNA/RNA, peptide-based vectors, and polymeric vectors, as well as viral platforms including adeno-associated virus vectors, adenovirus vectors, herpes simplex virus vectors, and retrovirus vectors, each presenting distinct manufacturing, analytics, and regulatory implications.
Therapeutic area segmentation further influences manufacturing strategy because the requirements for cardiovascular diseases, infectious diseases, monogenic disorders, and oncology vary in terms of patient population, dosing paradigms, and safety monitoring; cardiovascular programs focused on coronary artery disease or heart failure will prioritize scalable delivery and safety profiling, while infectious disease programs targeting hepatitis B or HIV emphasize robust vector dilution controls and durability metrics, and monogenic disorder programs for cystic fibrosis, hemophilia, or sickle cell anemia require highly personalized cell banking and cryopreservation logistics. Oncology programs addressing hematological malignancies and solid tumors impose different demands on cell expansion, potency assays, and release criteria. Application segmentation distinguishes clinical manufacturing from commercial manufacturing, and that distinction drives decisions around facility design, quality system maturity, and process robustness. Finally, end-user segmentation identifies the primary buyers and operators-contract research organizations, hospitals and clinics, pharmaceutical and biotech companies, and research institutes and academic institutions-each of which brings unique operational capabilities, procurement behaviors, and expectations for service level, turnaround time, and regulatory partnership.
How regional regulatory diversity, supply chain infrastructure, and clinical ecosystem strength are driving differentiated capacity planning and partnership models across global markets
Regional dynamics materially influence commercial strategy, capacity planning, and regulatory engagement as manufacturers and sponsors expand or consolidate operations. In the Americas, continuity of innovation, established clinical trial networks, and proximity to major commercial payers drive demand for scalable GMP manufacturing and robust analytics, encouraging investments in domestic fill-and-finish and vector production to support rapid clinical progression and commercialization readiness. Meanwhile, Europe, Middle East & Africa presents a heterogeneous regulatory and reimbursement landscape where early regulatory alignment and localized quality expectations necessitate flexible technology transfer approaches and region-specific supply chain adaptations, prompting multiregional qualification activities and tailored regulatory support services. The Asia-Pacific region combines manufacturing scale, cost-competitive supplier ecosystems, and rapidly growing R&D activity, which attracts investments in high-throughput production platforms and strategic partnerships, but stakeholders must contend with variable regulatory timelines and import-export controls that require nuanced logistical planning.
Across these geographies, cross-border collaboration and knowledge transfer remain essential. Decisions around where to site capacity, establish regional quality control laboratories, or partner with local clinical sites require evaluating not only cost and access but also regulatory harmonization, skilled workforce availability, and cold-chain infrastructure. As a result, successful players balance global platform standardization with regional adaptability to ensure compliance, supply resilience, and clinical continuity across heterogeneous markets.
Competitive differentiation in manufacturing services driven by GMP proficiency, integrated platform capabilities, and demonstrated regulatory support across complex program lifecycles
Competitive dynamics among service providers and technology suppliers are reshaping vendor selection criteria and partnership models. Leading companies differentiate through demonstrable GMP experience, validated analytics, scalable vector production capabilities, and robust technology transfer frameworks that reduce time and risk during scale-up. Strategic collaborations between CDMOs, specialty CROs, and platform technology owners create vertically integrated service suites that appeal to sponsors seeking single-source accountability for complex programs. At the same time, niche providers that offer deep expertise in areas such as viral vector manufacturing, advanced analytical testing, or cold-chain logistics capture value by solving specific technical bottlenecks during pivotal clinical phases.
Investor activity and strategic M&A continue to reconfigure the competitive landscape, as larger players seek to broaden service breadth while smaller, agile vendors emphasize speed and technical depth. Customers increasingly evaluate partners not only on cost and capacity but also on proven regulatory submissions, data integrity practices, and the ability to manage long-term stability and comparability. Consequently, the vendor selection process now prioritizes demonstrable end-to-end capabilities, transparent quality systems, and the capacity to co-develop transfer documents and control strategies that align with global regulatory expectations.
Actionable strategic priorities for leaders to enhance resilience, accelerate scale-up, and de-risk commercialization through modular manufacturing, supplier diversification, and proactive regulatory alignment
Industry leaders should prioritize building modular, platform-enabled manufacturing strategies that allow rapid pivoting across product formats while minimizing revalidation time. Investing in interoperable quality systems and standardized technology transfer templates enables smoother handoffs between development and commercial operations, improving timeline predictability. Additionally, cultivating a diversified supplier network and qualifying alternate domestic sources for critical reagents and disposables reduces exposure to tariff-induced and geopolitical supply disruptions, thereby enhancing program resilience.
Leaders should also embed regulatory engagement early and often, using iterative comparability plans and alignment meetings to de-risk late-stage surprises. Where appropriate, pursuing collaborative partnerships with specialized vendors for vector production, advanced analytics, or fill-and-finish services provides access to niche expertise without the capital burden of in-house expansion. Finally, workforce development and cross-training within facilities will be essential to maintain operational flexibility; investing in training programs and knowledge retention systems ensures that process know-how migrates smoothly across sites and partners, preserving quality and accelerating scale-up.
Robust mixed-method research approach combining expert interviews, vendor capability assessments, and documentary analysis to produce decision-oriented operational insights
This research synthesizes primary and secondary evidence, combining expert interviews, vendor capability assessments, and documentary analysis of regulatory guidance and industry practices. Primary inputs include structured interviews with manufacturing leaders, technology licensors, and clinical operations executives to capture real-world constraints and decision criteria. Secondary analysis encompasses public regulatory documents, technical white papers, peer-reviewed literature on gene editing and vector biology, and corporate disclosures that illustrate operational strategies and investment priorities.
Data synthesis follows a qualitative triangulation approach: themes identified in interviews are cross-validated against technical literature and vendor documentation to ensure consistency. Vendor capability matrices and process archetypes were created to compare service models, while case examples illustrate common pitfalls in technology transfer and scale-up. Throughout the methodology, emphasis was placed on preserving confidentiality of interview respondents and ensuring that analytical frameworks reflect current regulatory landscapes and technological realities. This mixed-method approach yields practical, decision-oriented insights without relying on proprietary market-sizing or forecasting models.
Synthesis of strategic imperatives emphasizing modular platforms, integrated regulatory planning, and supply resilience as prerequisites for successful translation of cell and gene therapies
In conclusion, cell and gene therapy manufacturing services now represent a strategic fulcrum that separates high-velocity development programs from those constrained by capacity, regulatory friction, or supply chain fragility. The interplay of advanced gene editing techniques, diversified vector platforms, and heightened regulatory attention demands a recalibration of partnership models, facility design, and supply resilience strategies. Organizations that adopt modular manufacturing platforms, institutionalize rigorous technology transfer practices, and cultivate diversified supplier networks will be better positioned to translate scientific promise into consistent clinical supply and sustainable commercial operations.
Moving forward, leaders should treat manufacturing strategy as an integrated component of therapeutic development rather than a downstream operational concern. By aligning technical choices, regulatory planning, and procurement strategy from early stages, sponsors and service providers can reduce program risk, accelerate patient access, and create enduring competitive advantage. The path to reliable supply is paved by intentional design, collaborative partnerships, and disciplined execution across the entire development continuum.
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
185 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Integration of closed automated bioreactor systems for large-scale CAR-T production to enhance reproducibility
- 5.2. Implementation of digital twin and process analytical technology for real-time monitoring of gene therapy manufacturing
- 5.3. Expansion of decentralized manufacturing networks using modular GMP suites to accelerate regional clinical supply
- 5.4. Standardization of raw material quality and supply chain traceability for viral vector and cell substrate components
- 5.5. Adoption of single-use manufacturing platforms to minimize cross-contamination and improve facility flexibility
- 5.6. Collaboration between CDMOs and academic centers for development of off-the-shelf allogeneic cell therapy pipelines
- 5.7. Regulatory harmonization efforts addressing potency assays and comparability for advanced therapy medicinal products
- 5.8. Investment in advanced viral vector purification technologies to increase yield and reduce downstream bottlenecks
- 5.9. Use of AI-driven process optimization for predictive maintenance and yield improvement in cell and gene therapy manufacturing
- 5.10. Development of cryopreservation protocols and supply chain logistics to support global distribution of living cell therapeutics
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Cell & Gene Therapy Manufacturing Services Market, by Service Type
- 8.1. Analytical & Quality Control Services
- 8.2. Cell Banking Services
- 8.3. Consulting Services
- 8.4. Fill & Finish Services
- 8.5. GMP Manufacturing Services
- 8.6. Process Development Services
- 8.7. Regulatory Support Services
- 8.8. Supply Chain & Logistics Services
- 8.9. Technology Transfer Services
- 8.10. Vector Production Services
- 9. Cell & Gene Therapy Manufacturing Services Market, by Technology Type
- 9.1. Gene Editing
- 9.1.1. CRISPR/Cas9
- 9.1.2. Transcription Activator-Like Effector Nucleases
- 9.1.3. Zinc Finger Nucleases
- 9.2. Vectors
- 9.2.1. Non-Viral Vectors
- 9.2.1.1. Cationic Lipids
- 9.2.1.2. Chitosan-Based Vectors
- 9.2.1.3. Dendrimers
- 9.2.1.4. Inorganic Nanoparticles
- 9.2.1.5. Liposomes
- 9.2.1.6. Naked DNA/RNA
- 9.2.1.7. Peptide-Based Vectors
- 9.2.1.8. Polymeric Vectors
- 9.2.2. Viral Vectors
- 9.2.2.1. Adeno-Associated Virus (AAV) Vectors
- 9.2.2.2. Adenovirus Vectors
- 9.2.2.3. Herpes Simplex Virus (HSV) Vectors
- 9.2.2.4. Retrovirus Vectors
- 10. Cell & Gene Therapy Manufacturing Services Market, by Therapeutic Area
- 10.1. Cardiovascular Diseases
- 10.1.1. Coronary Artery Disease
- 10.1.2. Heart Failure
- 10.2. Infectious Diseases
- 10.2.1. Hepatitis B
- 10.2.2. HIV
- 10.3. Monogenic Disorders
- 10.3.1. Cystic Fibrosis
- 10.3.2. Hemophilia
- 10.3.3. Sickle Cell Anemia
- 10.4. Oncology
- 10.4.1. Hematological Malignancies
- 10.4.2. Solid Tumors
- 11. Cell & Gene Therapy Manufacturing Services Market, by Application
- 11.1. Clinical Manufacturing
- 11.2. Commercial Manufacturing
- 12. Cell & Gene Therapy Manufacturing Services Market, by End-User
- 12.1. Contract Research Organizations
- 12.2. Hospitals & Clinics
- 12.3. Pharmaceutical & Biotech Companies
- 12.4. Research Institutes & Academic Institutions
- 13. Cell & Gene Therapy Manufacturing Services Market, by Region
- 13.1. Americas
- 13.1.1. North America
- 13.1.2. Latin America
- 13.2. Europe, Middle East & Africa
- 13.2.1. Europe
- 13.2.2. Middle East
- 13.2.3. Africa
- 13.3. Asia-Pacific
- 14. Cell & Gene Therapy Manufacturing Services Market, by Group
- 14.1. ASEAN
- 14.2. GCC
- 14.3. European Union
- 14.4. BRICS
- 14.5. G7
- 14.6. NATO
- 15. Cell & Gene Therapy Manufacturing Services Market, by Country
- 15.1. United States
- 15.2. Canada
- 15.3. Mexico
- 15.4. Brazil
- 15.5. United Kingdom
- 15.6. Germany
- 15.7. France
- 15.8. Russia
- 15.9. Italy
- 15.10. Spain
- 15.11. China
- 15.12. India
- 15.13. Japan
- 15.14. Australia
- 15.15. South Korea
- 16. Competitive Landscape
- 16.1. Market Share Analysis, 2024
- 16.2. FPNV Positioning Matrix, 2024
- 16.3. Competitive Analysis
- 16.3.1. Advanced BioScience Laboratories, Inc. by Institut Mérieux
- 16.3.2. AGC Biologics
- 16.3.3. AmplifyBio
- 16.3.4. Bio-Techne Corporation
- 16.3.5. C.H. Boehringer Sohn AG & Co. KG
- 16.3.6. Catalent, Inc.
- 16.3.7. Cell Therapies Pty Ltd.
- 16.3.8. Cell-Easy
- 16.3.9. Charles River Laboratories International, Inc.
- 16.3.10. Danaher Corporation
- 16.3.11. eXmoor Pharma Concepts Limited
- 16.3.12. FUJIFILM Diosynth Biotechnologies
- 16.3.13. Genezen Laboratories, Inc.
- 16.3.14. Laboratory Corporation of America Holdings
- 16.3.15. Lonza Group AG
- 16.3.16. Merck KGaA
- 16.3.17. Miltenyi Biotec B.V. & Co. KG
- 16.3.18. Minaris Regenerative Medicine GmbH by Resonac Corporation
- 16.3.19. Nikon Corporation
- 16.3.20. Novartis AG
- 16.3.21. Oxford Biomedica PLC
- 16.3.22. ProPharma Group Holdings, LLC
- 16.3.23. Recipharm AB
- 16.3.24. Samsung Biologics Co., Ltd.
- 16.3.25. SGS S.A.
- 16.3.26. STEMCELL Technologies Inc.
- 16.3.27. Takara Bio Inc.
- 16.3.28. Thermo Fisher Scientific Inc.
- 16.3.29. uBriGene Biosciences Inc.
- 16.3.30. WuXi AppTec Co., Ltd.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
